Monkeypox Proctitis: A Case of Targeted Treatment With Tecovirimat

Monkeypox (MPX) is an exanthematous disease first identified in the 1950s, associated with animals in Central and Western Africa, and has since been found sporadically worldwide. In May 2022, a returning family from Nigeria tested positive for MPX, which marked the onset of the current outbreak. It has now become a disease of concern in most parts of the world. The current standings are nearing 90,000 cases, with numbers increasing daily. The United States reported 29,711 cases so far. The characteristic exanthem of MPX is known to be present ubiquitously on the human habitus, with recent reports describing anogenital and mucosal lesions. Here, we present a rare case of a 43-year-old male presenting with excruciating perianal pain and purulent discharge, found to have proctitis secondary to MPX, and subsequently treated with Tecovirimat, a targeted antiviral therapy.

[1]  A. Antinori,et al.  Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. , 2022, The New England journal of medicine.

[2]  F. Rodríguez‐Artalejo,et al.  Monkeypox in humans: a new outbreak , 2022, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[3]  N. H. Brockmeyer As monkeypox goes sexual: a public health perspective , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  P. Biddinger,et al.  Case 24-2022: A 31-Year-Old Man with Perianal and Penile Ulcers, Rectal Pain, and Rash. , 2022, The New England journal of medicine.

[5]  Jennifer L. Small,et al.  Clinical features and management of human monkeypox: a retrospective observational study in the UK , 2022, The Lancet. Infectious diseases.

[6]  Y. Yoshikawa Monkeypox. , 1973, Releve epidemiologique hebdomadaire.